EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512

Inés Bleriot iD, Lucía Blasco iD, Patricia Fernández-Grela, Laura Fernández-García, Lucia Armán, Clara Ibarguren, Concha Ortiz-Cartagena, Antonio Barrio-Pujante, José Ramón Paño iD, Jesús Oteo-Iglesias, María Tomás iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01935-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Inés Bleriot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain. Hauptthemen laut MEDLINE: Klebsiella pneumoniae, Phage Therapy, Anti-Bacterial Agents, Klebsiella Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The widespread incidence of antimicrobial resistance has created renewed interest in the use of alternative antimicrobial treatments such as phage therapy. Phages are viruses that infect bacteria and generally have a narrow bacteria host-range. Combining phages with antibiotics can prevent the emergence of bacterial resistance. The aim of the present study was to develop phage therapy medical products (PTMPs) targeting clinical isolates of carbapenem-producing Klebsiella pneumoniae belonging to the high-risk clone ST512. From a collection of 22 seed of lytic phages sequenced belonging to MePRAM collection (Spanish Health Precision Medicine Project against Antimicrobial Resistance), four were used to generate PTMPs (CAC_Kpn1 and CAC_Kpn2). These PTMPs were partly active against three of the clinical strains of clone ST512 (A, B, and C). The use of Appelmans method in the CAC_Kpn1_ad (adapted CAC_Kpn1) yielded a significant increase in the efficacy against strain A, while adapted CAC_Kpn2 (CAC_Kpn2_ad) only effectively reduced bacterial survival when combined with ½ × MIC ß-lactam antibiotic meropenem for 24 h in clinical strains B and C, showed after this time, resistance to PTMPs. In addition, the amounts of endotoxin released by the PTMPs were quantified and subsequently reduced in preparation for in vivo use of the PTMPs in the Galleria mellonella infection model, confirming the in vitro results from the CAC_Kpn1_ad and CAC_Kpn2_ad. To sum up, the preparation of two PTMPs and their subsequent adaptation can be a good approach to solve part of the occurrence of antimicrobial resistance. In addition, the use of the larval model is an effective method to discriminate the efficacy of in vivo treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Klebsiella pneumoniaePhage TherapyAnti-Bacterial AgentsKlebsiella InfectionsBacteriophagesAnimalsMicrobial Sensitivity TestsMeropenemHumansMothsLarva

Stichwörter der Autor:innen

Galleria mellonellaKlebsiella pneumoniaeendotoxinsphage therapy medical products (PTMPs)phage-antibiotic synergy

Substanzen

Anti-Bacterial AgentsMeropenem

Autor:innen und Institutionen

  • Departamento de Microbiología-Hospital A Coruña (HUAC), Grupo de Microbiología Traslacional y Multidisciplinar (Micro-TM), A Coruña, Spain.
  • Grupo de Estudio de Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) en nombre de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Madrid, Spain.
  • Hospital Clínico Universitario "Lozano Blesa", Instituto de Investigación Sanitaria Aragón, Zaragoza, Aragon, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Community of Madrid, Spain.
  • MEPRAM, Proyecto de Medicina de Precisión contra las resistencias Antimicrobianas, Madrid, Spain.
  • Laboratorio de Referencia e Investigación de Resistencias Antibióticas e Infecciones Sanitarias, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain.

ORCID-Profile: Inés Bleriot, Lucía Blasco, José Ramón Paño, María Tomás

Zitieren

APA

Bleriot, I., Blasco, L., Fernández-Grela, P., Fernández-García, L., Armán, L., Ibarguren, C., Ortiz-Cartagena, C., Barrio-Pujante, A., Paño, J. R., Oteo-Iglesias, J., & Tomás, M. (2025). Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01935-24

Vancouver

Bleriot I, Blasco L, Fernández-Grela P, Fernández-García L, Armán L, Ibarguren C, et al. Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01935-24

BibTeX
@article{Bleriot2025,
  author = {Bleriot, Inés and Blasco, Lucía and Fernández-Grela, Patricia and Fernández-García, Laura and Armán, Lucia and Ibarguren, Clara and Ortiz-Cartagena, Concha and Barrio-Pujante, Antonio and Paño, José Ramón and Oteo-Iglesias, Jesús and Tomás, María},
  title = {Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01935-24}
}
Kostenlos starten →